Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
National Comprehensive Cancer Network
September 12, 2017
Esmo 2017 – Pharmamar and Abbvie fight it out in small-cell lung cancer
May 09, 2017
ELCC – Physicians look for progress in mesothelioma
October 25, 2016
Early Keytruda approval and Bristol’s other nasty surprises
June 07, 2016
Asco 2016 – Mirati takes home the share price wooden spoon
January 12, 2016
JP Morgan – Jumping in front of the cancer immunotherapy parade
December 21, 2015
A fresh Keytruda challenge to Opdivo and small molecules
October 27, 2015
Keynote and compendium guidelines come to Keytruda’s aid
October 12, 2015
Opdivo steals Keytruda’s thunder – again
March 25, 2015
Melanoma blow confirms threats to Yervoy before other crucial readouts
March 05, 2015
FDA surprises everyone with super-fast Opdivo lung cancer approval
November 12, 2014
Therapeutic focus – Survival benefit still eludes ovarian cancer trials
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
October 22, 2019
Shock revelation sees Biogen erase its aducanumab losses
October 22, 2019
Vertex’s double cystic fibrosis surprise
October 23, 2019
Bristol might play a role in front-line lung cancer after all
October 23, 2019
Bloated on arrival? Biotech's weightiest new issues
October 14, 2019
Uncovering biopharma’s hidden treasures
